Lipid microsphere formulation containing rifampicin targets alveolar macrophages

Drug Delivery

Volumn 15, Issue 3, 2008, Pages 169-175

  Takenaga, M ^a   Ohta, Y ^a   Tokura, Y ^a   Hamaguchi, A ^a   Igarashi, R ^a   Disratthakit, A ^b   Doi, N ^b  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

Alveolar Macrophage; Lipid Microspheres; Mycobacterium tuberculosis; Pulmonary Delivery; Rifampicin

Indexed keywords

LIPID; MICROSPHERE; RIFAMPICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; CONFOCAL LASER MICROSCOPY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG UPTAKE; ENCAPSULATION; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LIVER; LUNG; LUNG ALVEOLUS MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; DRUG DELIVERY SYSTEMS; INJECTIONS, SPINAL; KIDNEY; LIPIDS; LIVER; LUNG; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED ICR; MICROSPHERES; MYOCARDIUM; RATS; RATS, WISTAR; RIFAMPIN; SPLEEN; TISSUE DISTRIBUTION; TRITIUM;

EID: 41549130440     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540801952530     Document Type: Article

References (33)

1. Deol, P., Khuller, G. K., and Joshi, K. 1997a. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother. 41:1211-1214.
2. Deol, P., and Khuller, G. K. 1997b. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys. Acta 1334:162-172.
3. Drobniewski, F., Nikolayevsky, V., Asmolov, A., Bazhora, Y., and Servetsky, S. 2005. Increasing trends in HIV and TB rates in Odessa and the Ukraine. Int. J. Std. AIDS 16:374-378.
4. Dutt, M., and Khuller, G. K. 2001. Chemotherapy ofMycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly (DL-lactide-co-glycolide) microparticles. J. Antimicrob. Chemother. 47:829-835.
5. Edwards, D. A., Hanes, J., Caponetti G, Hrkach J, Ben-Jebria A, Eskew, M. L., Mintzes, J., Deaver, D., Lotan, N., and Langer, R. 1997. Large porous particles for pulmonary drug delivery. Science 276:1868-1871.
6. 1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy. Drugs Exptl. Clin. Res. 12:681-685.
7. Igarashi, R., Takenaga, M., and Matsuda, T. 1996. Distribution of a lipid microsphere preparation. Adv. Drug Del. Rev. 20:147-154.
8. Ikegami, M., Na, C.-L., Korfhagen, T. R., and Whitsett, J. A. 2005. Surfactant protein Dinfluences surfactant ultrastructure and uptake by alveolar type II cells. Am. J. Physiol. Lung Cell Mol. Physiol. 288: L552-L561.
9. Justesen, U. S., Andersen, A. B., Klitgaard, N. A., Brosen, K., Gerstoft, J., and Pedersen, C. 2004. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin. Infect. Dis. 38: 426-429.
10. Justo, O. R., and Moraes, A. M. 2003. Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug Del. 10: 201-207.
11. 99mTc-labeled lipid microspheres (LM) would be useful for an imaging study of those diseases. Jpn. J. Inflam. 7:551-557.
12. Makino, K., Nakajima, T., Shikamura, M., Ito, F., Ando, S., Kochi, C., Inagawa, H., Soma, G., and Terada, H. 2004. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf. Biointerf. 36:35-42.
13. Mizushima, Y., Hoshi, K., Aihara, H., and Kurachi, M. 1983. Inhibition of bronchoconstriction by aerosol of a lipid emulsion containing prostaglandin E1. J. Pharm. Pharmacol. 35: 397.
14. 1 to vascular lesions. Prostagl. Leukotr. Essent. Fatty Acids 41:269-272.
15. Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., and Kivisto, K. T. 2003. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin. Pharmacokinet. 42: 819-850.
16. O'Hara, P., and Hickey, A. J. 2000. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharmaceut. Res. 17:955-956.
17. Pandey, R., Sharma, A., Zahoor, A., Sharma, S., Khuller, G.K., and Prasad, B. 2003. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52:981-986.
18. Pandey, R., and Khuller, G. K. 2004. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J. Antimicrob. Chemother. 54:266-268.
19. Pillai, R. S., Yeates, D. B., Miller, I. F., and Hickey, A. J. 1998. Controlled dissolution from wax-coated aerosol particles in canine lungs. J. Appl. Physiol. 84:717-725.
20. Russell, D. G. 2001. Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell Biol. 2: 569-577.
21. Salem, I. I., Flasher, D. L., and Duzgunes, N. 2005. Liposome- encapsulated antibiotics. Meth. Enzymol. 391:261-291.
22. Sharma, A., Pandey, R., Sharma, S., and Khuller, G. K. 2004. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int. J. Antimicrob. Agents 24:599-604.
23. Shoji, Y., Mizushima, Y., Yanagawa, A., and Yonaha, T. 1985. Electron microscopic studies on tissue distribution of lipid microspheres used as drug delivery carriers. Drugs Exptl. Clin. Res. 11:601-609.
24. Suarez, S., O'Hara, P., Kazantseva,M., Newcomer,C. E., Hopfer, R., McMurray, D. N., and Hickey, A. J. 2001a. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res. 18:1315-1319.
25. Suarez, S., O'Hara, P., Kazantseva,M., Newcomer,C. E., Hopfer, R., McMurray, D. N., and Hickey, A. J. 2001b. Airways delivery of rifampin. J. Antimicrob. Chemother. 48:431-434.
26. Tasdug, S. A., Peerzada, K.,Koul, S., Bhat, R. and Johri, R. K. 2005. Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin. Hepatol. Res. 31:132-135.
27. Takenaga, M., Igarashi, R., Tsuji, H., and Mizushima, Y. 1993a. Enhanced antitumor activity and reduced toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea administration in lipid microspheres to tumor-bearing mice. Jpn. J. Cancer Res. 84:1078-1085.
28. 2 receptor antagonist aerosol inhalation. J. Drug Targ. 1:293-301.
29. Takenaga, M. 1996. Application of lipid microspheres for the treatment of cancer. Adv. Drug Del. Rev. 20:209-219.
30. Takenaga, M., Igarashi, R., Matsumoto, K., Takeuchi, J., Mizushima, N., Nakayama, T., Morizawa, Y., and Mizushima, Y. 1999. Lipid microsphere preparation of a lipophilic ceramide derivative suppresses colony formation in a murine experimental pulmonary metastasis model. J. Drug Targ. 7:187-195.
31. Takenaga, M., Igarashi, R., and Mizushima,Y. 2000. Possibility of LipoY-24180 as an injectable drug and an inhaler for the treatment of bronchoconstriction. J. Allerg. Int. 14:143-149.
32. Ul-Ain, Q., Sharma, S., and Khuller, G.K. 2003. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. Antimicrob. Agents Chemother. 47:3005-3007.
33. Yoshida, A., Matsumoto, M., Hashizume, H., Oba, Y., Tomishige, T., Inagawa, H., Kohchi, C., Hino, M., Ito, F., Tomoda, K., Nakajima, T, Makino, K., Terada, H., Hori, H., and Soma, G. 2006. Selective delivery of rifampicin incorporated into poly(dl-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guerin. Microbes. Infect. 8:2484-2491.